rspНаучно-практическая ревматологияRheumatology Science and Practice1995-44841995-4492IMA-PRESS, LLC10.14412/1995-4484-2020-207-213rsp-2879Research ArticleПРОГРАММА НЕПРЕРЫВНОГО ПОСЛЕДИПЛОМНОГО ОБРАЗОВАНИЯ ВРАЧЕЙPOSTGRADUATE PROGRAM OF CONTINUING MEDICAL EDUCATIONВирус гепатита В и ревматические болезниHEPATITIS B VIRUS AND RHEUMATIC DISEASEShttps://orcid.org/0000-0001-7091-2054БеловБ. С.BelovB. S.

заведующий лабораторией изучения коморбидных инфекций и мониторинга безопасности лекарственной терапии, профессор, докт. мед. наук

115522, Москва, Каширское шоссе, 34А

belovbor@yandex.ruhttps://orcid.org/0000-0002-3160-2771АбдурахмановД. Т.AbdurakhmanovD. T.

профессор кафедры внутренних, профессиональных болезней и ревматологии, докт. мед. наук

119991, Москва, ул. Трубецкая, 8, стр. 2

ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»РоссияV.A. Nasonova Research Institute of RheumatologyRussian FederationФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова» Минздрава России (Сеченовский Университет)РоссияI.M. Sechenov First Moscow State Medical University (Sechenov University), Ministry of Health of RussiaRussian Federation202026042020582207213Copyright © Белов Б.С., Абдурахманов Д.Т., 20202020Белов Б.С., Абдурахманов Д.Т.Belov B.S., Abdurakhmanov D.T.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://rsp.mediar-press.net/rsp/article/view/2879ревматические заболеванияиммуносупрессивная терапияхронический вирусный гепатит Вреактивацияпрофилактикаrheumatic diseasesimmunosuppressive therapychronic viral hepatitis BreactivationpreventionReferencesThe Polaris Observatory Collaborators. Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study. Lancet Gastroenterol Hepatol. 2018;3:383-403. doi: 10.1016/S2468-1253(18)30056-6The Polaris Observatory Collaborators. Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study. Lancet Gastroenterol Hepatol. 2018;3:383-403. doi: 10.1016/S2468-1253(18)30056-6Ющук НД, Знойко ОО. Гепатит В. В кн.: Ющук НД, Венгеров ЮА, редакторы. Инфекционные болезни: Национальное руководство. Москва: ГЭОТАР-Медиа; 2009. С. 616-36.Yushchuk ND, Znojko OO. Gepatit V. In: Yushchuk ND, Vengerov YuYa, editors. Infekcionnye bolezni: Nacional'noe rukovodstvo [Infectious Diseases: National Guidelines]. Moscow: GEOTAR-Media; 2009. P. 616-36 (In Russ.)EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;67(2):370-98. doi: 10.1016/j.jhep.2017.03.021EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;67(2):370-98. doi: 10.1016/j.jhep.2017.03.021Cacoub P, Terrier B. Hepatitis B-related autoimmune manifestations. Rheum Dis Clin North Am. 2009;35(1):125-37. doi: 10.1016/j.rdc.2009.03.006Cacoub P, Terrier B. Hepatitis B-related autoimmune manifestations. Rheum Dis Clin North Am. 2009;35(1):125-37. doi: 10.1016/j.rdc.2009.03.006Vukatana G, Gamal N, Trevisani M, et al. Serological prevalence of hepatitis B virus infection among patients with different rheumatic disease: A prospective study. Ann Rheum Dis. 2014;73(Suppl 2):281. doi: 10.1136/annrheumdis-2014-eular.5467Vukatana G, Gamal N, Trevisani M, et al. Serological prevalence of hepatitis B virus infection among patients with different rheumatic disease: A prospective study. Ann Rheum Dis. 2014;73(Suppl 2):281. doi: 10.1136/annrheumdis-2014-eular.5467Cacoub B, Saadoun D, Bourliere M, et al. Hepatitis B virus genotypes and extrahepatic manifestations. J Hepatol. 2005;43:764-70. doi: 10.1016/j.jhep.2005.05.029Cacoub B, Saadoun D, Bourliere M, et al. Hepatitis B virus genotypes and extrahepatic manifestations. J Hepatol. 2005;43:764-70. doi: 10.1016/j.jhep.2005.05.029Pagnoux C, Seror R, Henegar C, et al. Clinical features and outcomes in 348 patients with polyarteritis nodosa: a systematic retrospective study of patients diagnosed between 1963 and 2005 and entered into the French Vasculitis Study Group Database. Arthritis Rheum. 2010;62(2):616-26. doi: 10.1002/art.27240Pagnoux C, Seror R, Henegar C, et al. Clinical features and outcomes in 348 patients with polyarteritis nodosa: a systematic retrospective study of patients diagnosed between 1963 and 2005 and entered into the French Vasculitis Study Group Database. Arthritis Rheum. 2010;62(2):616-26. doi: 10.1002/art.27240Jennette JC, Falk RJ, Bacon PA, et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum. 2013;65(1):1-11. doi: 10.1002/art.37715Jennette JC, Falk RJ, Bacon PA, et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum. 2013;65(1):1-11. doi: 10.1002/art.37715Terrier B, Marie I, Lacraz A, et al. Non HCV-related infectious cryoglobulinemia vasculitis: results from the French nation-wide CryoVas survey and systematic review of the literature. J Autoimmun. 2015;65:74-81. doi: 10.1016/j.jaut.2015.08.008Terrier B, Marie I, Lacraz A, et al. Non HCV-related infectious cryoglobulinemia vasculitis: results from the French nation-wide CryoVas survey and systematic review of the literature. J Autoimmun. 2015;65:74-81. doi: 10.1016/j.jaut.2015.08.008Mazzaro C, Maso LD, Mauro E, et al. Survival and prognostic factors in mixed cryoglobulinemia: data from 246 cases. Diseases. 2018;6(2). pii: E35. doi: 10.3390/diseases6020035Mazzaro C, Maso LD, Mauro E, et al. Survival and prognostic factors in mixed cryoglobulinemia: data from 246 cases. Diseases. 2018;6(2). pii: E35. doi: 10.3390/diseases6020035Mazzaro C, Dal Maso L, Urraro T, et al. Hepatitis B virus related cryoglobulinemic vasculitis: A multicentre open label study from the Gruppo Italiano di Studio delle Crioglobulinemie – GISC. Dig Liver Dis. 2016 Jul;48(7):780-4. doi: 10.1016/j.dld.2016.03.018Mazzaro C, Dal Maso L, Urraro T, et al. Hepatitis B virus related cryoglobulinemic vasculitis: A multicentre open label study from the Gruppo Italiano di Studio delle Crioglobulinemie – GISC. Dig Liver Dis. 2016 Jul;48(7):780-4. doi: 10.1016/j.dld.2016.03.018D’Amico E, Pace-Palitti V, Di Lembo E, Palazzi C. Successful treatment of hepatitis B virus infection and related cryoglobulinaemic purpura with nucleoside/nucleotide analogues. Clin Exp Rheumatol. 2013;31(1):155.D’Amico E, Pace-Palitti V, Di Lembo E, Palazzi C. Successful treatment of hepatitis B virus infection and related cryoglobulinaemic purpura with nucleoside/nucleotide analogues. Clin Exp Rheumatol. 2013;31(1):155.Vigano M, Martin P, Cappelletti M, Fabrizi F. HBV-associated cryoglobulinemic vasculitis: remission after antiviral therapy with entecavir. Kidney Blood Press Res. 2014;39(1):65-73. doi: 10.1159/000355778Vigano M, Martin P, Cappelletti M, Fabrizi F. HBV-associated cryoglobulinemic vasculitis: remission after antiviral therapy with entecavir. Kidney Blood Press Res. 2014;39(1):65-73. doi: 10.1159/000355778Charpin C, Guis S, Colson P, et al. Safety of TNF-blocking agents in rheumatic patients with serology suggesting past hepatitis B state: results from a cohort of 21 patients. Arthritis Res Ther. 2009;11(6):R179. doi: 10.1186/ar2868Charpin C, Guis S, Colson P, et al. Safety of TNF-blocking agents in rheumatic patients with serology suggesting past hepatitis B state: results from a cohort of 21 patients. Arthritis Res Ther. 2009;11(6):R179. doi: 10.1186/ar2868Vassilopoulos D, Apostolopoulou A, Hadziyannis E, et al. Longterm safety of anti- TNF treatment in patients with rheumatic diseases and chronic or resolved hepatitis B virus infection. Ann Rheum Dis. 2010 Jul;69(7):1352-5. doi: 10.1136/ard.2009.127233Vassilopoulos D, Apostolopoulou A, Hadziyannis E, et al. Longterm safety of anti- TNF treatment in patients with rheumatic diseases and chronic or resolved hepatitis B virus infection. Ann Rheum Dis. 2010 Jul;69(7):1352-5. doi: 10.1136/ard.2009.127233Caporali R, Bobbio-Pallavicini F, Atzeni F, et al. Safety of tumor necrosis factor alpha blockers in hepatitis B virus occult carriers (hepatitis B surface antigen negative/anti-hepatitis B core antigen positive) with rheumatic diseases. Arthritis Care Res (Hoboken). 2010 Jun;62(6):749-54. doi: 10.1002/acr.20130Caporali R, Bobbio-Pallavicini F, Atzeni F, et al. Safety of tumor necrosis factor alpha blockers in hepatitis B virus occult carriers (hepatitis B surface antigen negative/anti-hepatitis B core antigen positive) with rheumatic diseases. Arthritis Care Res (Hoboken). 2010 Jun;62(6):749-54. doi: 10.1002/acr.20130Giardina AR, Ferraro D, Ciccia F, et al. No detection of occult HBV-DNA in patients with various rheumatic diseases treated with anti-TNF agents: a two-year prospective study. Clin Exp Rheumatol. 2013 Jan-Feb;31(1):25-30.Giardina AR, Ferraro D, Ciccia F, et al. No detection of occult HBV-DNA in patients with various rheumatic diseases treated with anti-TNF agents: a two-year prospective study. Clin Exp Rheumatol. 2013 Jan-Feb;31(1):25-30.Biondo MI, Germano V, Pietrosanti M, et al. Lack of hepatitis B virus reactivation after anti-tumour necrosis factor treatment in potential occult carriers with chronic inflammatory arthropathies. Eur J Intern Med. 2014 Jun;25(5):482-4. doi: 10.1016/j.ejim.2013.11.014Biondo MI, Germano V, Pietrosanti M, et al. Lack of hepatitis B virus reactivation after anti-tumour necrosis factor treatment in potential occult carriers with chronic inflammatory arthropathies. Eur J Intern Med. 2014 Jun;25(5):482-4. doi: 10.1016/j.ejim.2013.11.014Ballanti E, Conigliaro P, Chimenti MS, et al. Use of anti-tumor necrosis factor alpha therapy in patients with concurrent rheumatoid arthritis and hepatitis B or hepatitis C: a retrospective analysis of 32 patients. Drug Dev Res. 2014 Nov;75 Suppl 1:S42-5. doi: 10.1002/ddr.21193Ballanti E, Conigliaro P, Chimenti MS, et al. Use of anti-tumor necrosis factor alpha therapy in patients with concurrent rheumatoid arthritis and hepatitis B or hepatitis C: a retrospective analysis of 32 patients. Drug Dev Res. 2014 Nov;75 Suppl 1:S42-5. doi: 10.1002/ddr.21193Kato M, Atsumi T, Kurita T, et al. Hepatitis B virus reactivation by immunosuppressive therapy in patients with autoimmune diseases: risk analysis in Hepatitis B surface antigen-negative cases. J Rheumatol. 2011 Oct;38(10):2209-14. doi: 10.3899/jrheum.110289Kato M, Atsumi T, Kurita T, et al. Hepatitis B virus reactivation by immunosuppressive therapy in patients with autoimmune diseases: risk analysis in Hepatitis B surface antigen-negative cases. J Rheumatol. 2011 Oct;38(10):2209-14. doi: 10.3899/jrheum.110289Lan JL, Chen YM, Hsieh TY, et al. Kinetics of viral loads and risk of hepatitis B virus reactivation in hepatitis B core antibody-positive rheumatoid arthritis patients undergoing anti-tumour necrosis factor alpha therapy. Ann Rheum Dis. 2011 Oct;70(10):1719-25. doi: 10.1136/ard.2010.148783Lan JL, Chen YM, Hsieh TY, et al. Kinetics of viral loads and risk of hepatitis B virus reactivation in hepatitis B core antibody-positive rheumatoid arthritis patients undergoing anti-tumour necrosis factor alpha therapy. Ann Rheum Dis. 2011 Oct;70(10):1719-25. doi: 10.1136/ard.2010.148783Tan J, Zhou J, Zhao P, Wei J. Prospective study of HBV reactivation risk in rheumatoid arthritis patients who received conventional disease-modifying antirheumatic drugs. Clin Rheumatol 2012;31:1169-75. doi: 10.1007/s10067-012-1988-2Tan J, Zhou J, Zhao P, Wei J. Prospective study of HBV reactivation risk in rheumatoid arthritis patients who received conventional disease-modifying antirheumatic drugs. Clin Rheumatol 2012;31:1169-75. doi: 10.1007/s10067-012-1988-2Ye H, Zhang XW, Mu R, et al. Anti-TNF therapy in patients with HBV infection--analysis of 87 patients with inflammatory arthritis. Clin Rheumatol. 2014 Jan;33(1):119-23. doi: 10.1007/s10067-013-2385-1Ye H, Zhang XW, Mu R, et al. Anti-TNF therapy in patients with HBV infection--analysis of 87 patients with inflammatory arthritis. Clin Rheumatol. 2014 Jan;33(1):119-23. doi: 10.1007/s10067-013-2385-1Nakamura J, Nagashima T, Nagatani K, et al. Reactivation of hepatitis B virus in rheumatoid arthritis patients treated with biological disease-modifying antirheumatic drugs. Int J Rheum Dis. 2016 May;19(5):470-5. doi: 10.1111/1756-185X.12359Nakamura J, Nagashima T, Nagatani K, et al. Reactivation of hepatitis B virus in rheumatoid arthritis patients treated with biological disease-modifying antirheumatic drugs. Int J Rheum Dis. 2016 May;19(5):470-5. doi: 10.1111/1756-185X.12359Fukuda W, Hanyu T, Katayama M, et al. Incidence of hepatitis B virus reactivation in patients with resolved infection on immunosuppressive therapy for rheumatic disease: A multicentre, prospective, observational study in Japan. Ann Rheum Dis. 2017 Jun;76(6):1051-6. doi: 10.1136/annrheumdis-2016-209973Fukuda W, Hanyu T, Katayama M, et al. Incidence of hepatitis B virus reactivation in patients with resolved infection on immunosuppressive therapy for rheumatic disease: A multicentre, prospective, observational study in Japan. Ann Rheum Dis. 2017 Jun;76(6):1051-6. doi: 10.1136/annrheumdis-2016-209973American Association for the Study of Liver Diseases Emerging Trends Conference, Reactivation of Hepatitis B; March 21–22, 2013. Arlington, VA; 2013.American Association for the Study of Liver Diseases Emerging Trends Conference, Reactivation of Hepatitis B; March 21–22, 2013. Arlington, VA; 2013.Michel M, Duvoux C, Hezode C, Cherqui D. Fulminant hepatitis after infliximab in a patient with hepatitis B virus treated for an adult onset still's disease. J Rheumatol. 2003;30(7):1624-5.Michel M, Duvoux C, Hezode C, Cherqui D. Fulminant hepatitis after infliximab in a patient with hepatitis B virus treated for an adult onset still's disease. J Rheumatol. 2003;30(7):1624-5.Ostuni P, Botsios C, Punzi L, et al. Hepatitis B reactivation in a chronic hepatitis B surface antigen carrier with rheumatoid arthritis treated with infliximab and low dose methotrexate. Ann Rheum Dis. 2003;62(7):686-7. doi: 10.1136/ard.62.7.686Ostuni P, Botsios C, Punzi L, et al. Hepatitis B reactivation in a chronic hepatitis B surface antigen carrier with rheumatoid arthritis treated with infliximab and low dose methotrexate. Ann Rheum Dis. 2003;62(7):686-7. doi: 10.1136/ard.62.7.686Puro R, Schneider RJ. Tumor necrosis factor activates a conserved innate antiviral response to hepatitis B virus that destabilizes nucleocapsids and reduces nuclear viral DNA. J Virol. 2007;81(14):7351-62. doi: 10.1128/JVI.00554-07Puro R, Schneider RJ. Tumor necrosis factor activates a conserved innate antiviral response to hepatitis B virus that destabilizes nucleocapsids and reduces nuclear viral DNA. J Virol. 2007;81(14):7351-62. doi: 10.1128/JVI.00554-07Tien YC, Yen HH, Chiu YM. Incidence and clinical characteristics of hepatitis B virus reactivation in HBsAg-negative/HBcAbpositive patients receiving rituximab for rheumatoid arthritis. Clin Exp Rheumatol. 2017 Sep-Oct;35(5):831-6.Tien YC, Yen HH, Chiu YM. Incidence and clinical characteristics of hepatitis B virus reactivation in HBsAg-negative/HBcAbpositive patients receiving rituximab for rheumatoid arthritis. Clin Exp Rheumatol. 2017 Sep-Oct;35(5):831-6.Perez-Alvarez R, Diaz-Lagares C, Garcia-Hernandez F, et al. Hepatitis B virus (HBV) reactivation in patients receiving tumor necrosis factor (TNF)-targeted therapy: analysis of 257 cases. Medicine (Baltimore). 2011 Nov;90(6):359-71. doi: 10.1097/MD.0b013e3182380a76Perez-Alvarez R, Diaz-Lagares C, Garcia-Hernandez F, et al. Hepatitis B virus (HBV) reactivation in patients receiving tumor necrosis factor (TNF)-targeted therapy: analysis of 257 cases. Medicine (Baltimore). 2011 Nov;90(6):359-71. doi: 10.1097/MD.0b013e3182380a76Lin TC, Yoshida K, Tedeschi SK, et al. Risk of hepatitis B virus reactivation in patients with inflammatory arthritis receiving disease-modifying antirheumatic drugs: A systematic review and meta-analysis. Arthritis Care Res (Hoboken). 2018 May;70(5):724-31. doi: 10.1002/acr.23346Lin TC, Yoshida K, Tedeschi SK, et al. Risk of hepatitis B virus reactivation in patients with inflammatory arthritis receiving disease-modifying antirheumatic drugs: A systematic review and meta-analysis. Arthritis Care Res (Hoboken). 2018 May;70(5):724-31. doi: 10.1002/acr.23346Perrillo RP, Gish R, Falck-Ytter YT. American Gastroenterological Association Institute technical review on prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy. Gastroenterology. 2015 Jan;148(1):221-44.e3. doi: 10.1053/j.gastro.2014.10.038Perrillo RP, Gish R, Falck-Ytter YT. American Gastroenterological Association Institute technical review on prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy. Gastroenterology. 2015 Jan;148(1):221-44.e3. doi: 10.1053/j.gastro.2014.10.038Chen YM, Huang WN, Wu YD, et al. Reactivation of hepatitis B virus infection in patients with rheumatoid arthritis receiving tofacitinib: a real-world study. Ann Rheum Dis. 2018 May;77(5):780-2. doi: 10.1136/annrheumdis-2017-211322Chen YM, Huang WN, Wu YD, et al. Reactivation of hepatitis B virus infection in patients with rheumatoid arthritis receiving tofacitinib: a real-world study. Ann Rheum Dis. 2018 May;77(5):780-2. doi: 10.1136/annrheumdis-2017-211322Chiu HY, Hui RC, Huang YH, et al. Safety profile of secukinumab in treatment of patients with psoriasis and concurrent hepatitis B or C: A multicentric prospective cohort study. Acta Derm Venereol. 2018 Oct 10;98(9):829-34. doi: 10.2340/00015555-2989Chiu HY, Hui RC, Huang YH, et al. Safety profile of secukinumab in treatment of patients with psoriasis and concurrent hepatitis B or C: A multicentric prospective cohort study. Acta Derm Venereol. 2018 Oct 10;98(9):829-34. doi: 10.2340/00015555-2989Koutsianas C, Thomas K, Vassilopoulos D. Hepatitis B reactivation in rheumatic diseases: screening and prevention. Rheum Dis Clin North Am. 2017 Feb;43(1):133-49. doi: 10.1016/j.rdc.2016.09.012Koutsianas C, Thomas K, Vassilopoulos D. Hepatitis B reactivation in rheumatic diseases: screening and prevention. Rheum Dis Clin North Am. 2017 Feb;43(1):133-49. doi: 10.1016/j.rdc.2016.09.012Mok CC. Hepatitis B and C infection in patients undergoing biologic and targeted therapies for rheumatic diseases. Best Pract Res Clin Rheumatol. 2018;32(6):767-80. doi: 10.1016/j.berh.2019.03.008Mok CC. Hepatitis B and C infection in patients undergoing biologic and targeted therapies for rheumatic diseases. Best Pract Res Clin Rheumatol. 2018;32(6):767-80. doi: 10.1016/j.berh.2019.03.008

The authors declare that there are no conflicts of interest present.